Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Satoshi Yoshiba"'
Publikováno v:
Folia Pharmacologica Japonica. 154:352-361
Mirogabalin, a novel ligand for the α2δ subunit of voltage-gated calcium channels, has been approved for the treatment of peripheral neuropathic pain including painful diabetic peripheral neuropathy (DPNP) and postherpetic neuralgia (PHN) in Japan.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39bb330c9cab841bd65f3a43c3296e00
https://doi.org/10.1254/fpj.154.352
https://doi.org/10.1254/fpj.154.352
Publikováno v:
Journal of Thrombosis and Thrombolysis
This randomized double-blind crossover study aimed to investigate the influence of cytochrome P450 (CYP) 2C19 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke treated with clopidogrel. Patients received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::021f828b5fc6ebb6eb97468ca93f5b8e
https://doi.org/10.1007/s11239-018-1714-2
https://doi.org/10.1007/s11239-018-1714-2
Publikováno v:
Journal of Thrombosis and Thrombolysis
Prasugrel, a novel P2Y12 receptor antagonist, has been shown to be more effective than clopidogrel for preventing cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. We investigated the dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f21d195964691b171464e507e0b00f3b
https://pubmed.ncbi.nlm.nih.gov/31643039
https://pubmed.ncbi.nlm.nih.gov/31643039
Publikováno v:
The Journal of Clinical Pharmacology. 51:243-251
This open-label, single-dose study assessed the safety and pharmacokinetics of laninamivir, a new long-acting neuraminidase inhibitor, after an inhaled 20-mg dose of its prodrug, CS-8958, to a total of 20 subjects with normal, mild, moderate, or seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78adfc6da2b601d7d6e2ec9b7c059a8
https://doi.org/10.1177/0091270010361914
https://doi.org/10.1177/0091270010361914
Publikováno v:
Cancer chemotherapy and pharmacology. 77(5)
The purpose of this analysis was to develop a population pharmacokinetic (PK) model for patritumab, a fully human monoclonal antibody that targets human epidermal growth factor receptor 3. A total of 833 serum concentrations were included in this ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70b48f97b969a156ddd9f6081a4c841
https://pubmed.ncbi.nlm.nih.gov/27017616
https://pubmed.ncbi.nlm.nih.gov/27017616
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Pharmacokinetic profiles of laninamivir after a single inhalation of laninamivir octanoate (LO), a prodrug of laninamivir, using a newly developed easy-to-use inhaler were evaluated in healthy volunteers. LO appeared rapidly in plasma after an inhale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d58099f07f8eab7776aa3c5356950f52
https://doi.org/10.4172/jbb.1000048
https://doi.org/10.4172/jbb.1000048
Publikováno v:
Journal of clinical pharmacology. 50(11)
Phase 1 studies of laninamivir, a novel long-acting neuraminidase inhibitor, were carried out to assess its safety, tolerability, and pharmacokinetics after inhaled administration of its prodrug, CS-8958. Healthy male volunteers (total N = 76) partic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be87df78a0bf3ec153fa8914065cd68
https://pubmed.ncbi.nlm.nih.gov/20145259
https://pubmed.ncbi.nlm.nih.gov/20145259
Publikováno v:
Journal of Clinical Oncology. 32:2587-2587
2587 Background: Patritumab is a fully human antibody specific to HER3, a HER family receptor implicated in tumor resistance to anticancer treatment. In order to support patritumab dose recommendat...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bec2cdef1f407a4c671243671222833c
https://doi.org/10.1200/jco.2014.32.15_suppl.2587
https://doi.org/10.1200/jco.2014.32.15_suppl.2587